Management of Low-Risk Prostate Cancer in a 66-Year-Old Male
Introduction to Active Surveillance
- The American Urological Association recommends active surveillance as the preferred management approach for patients with low-risk prostate cancer, characterized by a Gleason score ≤6, PSA <10 ng/mL, and normal digital rectal exam, rather than immediate radical prostatectomy 1, 2
Risk Classification
- A patient is classified as having low-risk prostate cancer based on the following criteria: Gleason score ≤6, PSA <10 ng/mL, normal digital rectal exam (clinical stage T1c), and negative imaging (MRI and bone scan) 1, 2
Active Surveillance Protocol
- The patient should follow a structured monitoring approach, including PSA measurement every 6 months 2, digital rectal examination every 12 months 1, repeat prostate biopsy every 12 months 2, and a first follow-up visit at 3 months to establish baseline 1, 2
Treatment Options
- If intervention becomes necessary, equivalent treatment options include radical prostatectomy with pelvic lymph node dissection 2, external beam radiation therapy (minimum 70 Gy in 2.0 Gy fractions) 1, and brachytherapy (permanent seed implants) 2
- The National Comprehensive Cancer Network recommends that these treatment options be considered for patients with localized disease, as they achieve similar long-term survival outcomes 3, 4, 5
Considerations for Active Treatment
- Active treatment should be considered if the Gleason score upgrades to ≥7 on repeat biopsy 1, PSA velocity >2.0 ng/mL/year 7, or if there is increased tumor volume on biopsy (>3 cores positive or >50% involvement per core) 1
Special Considerations
- For patients with significant comorbidities reducing life expectancy to <10 years, observation (watchful waiting) without curative intent may be more appropriate than active surveillance, as recommended by the American Academy of Family Physicians 6, 1
- Pelvic lymph node dissection is not necessary with PSA <10 ng/mL and Gleason score ≤6, according to the European Association of Urology 7, 4